BEDFORD, Mass.--(BUSINESS WIRE)--Jun. 2, 2015--
Ocular Therapeutix, Inc. (NASDAQ: OCUL) announced today that it has
commenced an underwritten public offering of 4,000,000 shares of its
common stock. The offering consists of 3,200,000 shares being offered by
the Company and 800,000 shares being offered by certain stockholders of
the Company. In addition, the selling stockholders are expected to grant
the underwriters of the offering an option for a period of 30 days to
purchase up to an additional 600,000 shares of the Company’s common
stock at the public offering price, less the underwriting discount.
Ocular Therapeutix will not receive any proceeds from the sale of shares
by the selling stockholders. The offering is subject to market and other
conditions, and there can be no assurance as to whether or when the
offering may be completed.
Morgan Stanley, Cowen and Company and RBC Capital Markets are acting as
joint book-running managers for the offering. Nomura and BTIG are acting
as co-managers for the offering. The offering is being made only by
means of a prospectus. Copies of the preliminary prospectus relating to
this offering may be obtained by contacting Morgan Stanley & Co. LLC,
Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New
York, NY 10014; Cowen and Company, LLC, c/o Broadridge Financial
Services, Attention: Prospectus Department, 1155 Long Island Avenue,
Edgewood, NY 11717; RBC Capital Markets, LLC, Attention: Equity
Syndicate, 200 Vesey Street, 8th Floor, New York, NY 10281; Nomura
Securities International, Inc., Attention: ECM Syndicate Department, 309
West 49th Street, 5th Floor, New York, NY 10019; or BTIG, LLC,
Attention: U.S. Syndicate, 825 3rd Avenue, 6th Floor, New York, NY 10022.
A registration statement relating to these securities has been filed
with the U.S. Securities and Exchange Commission but has not yet become
effective. These securities may not be sold, nor may offers to buy be
accepted, prior to the time the registration statement becomes
effective. This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful, prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Ocular Therapeutix
Ocular Therapeutix, Inc. is a
biopharmaceutical company focused on the development and
commercialization of innovative therapies for diseases and conditions of
the eye using its proprietary hydrogel platform technology. Ocular
Therapeutix’s lead product candidates are in Phase 3 clinical
development for post-surgical ocular inflammation and pain, and Phase 2
clinical development for glaucoma, allergic conjunctivitis and
inflammatory dry eye disease. The Company is also evaluating
sustained-release injectable anti-VEGF drug depots for back-of-the-eye
diseases. Ocular Therapeutix’s first product, ReSure®
Sealant, is FDA-approved to seal corneal incisions following cataract
surgery.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150602006810/en/
Source: Ocular Therapeutix, Inc.
Investors
Ocular Therapeutix, Inc.
Brad Smith
Chief
Financial Officer
bsmith@ocutx.com
or
Burns
McClellan on behalf of Ocular Therapeutix
Kimberly Minarovich,
212-213-0006
kminarovich@burnsmc.com
or
Media
Ocular
Therapeutix, Inc.
Scott Corning
Vice President of Sales and
Marketing
scorning@ocutx.com